Novavax Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Boeing nears approval of 737 MAX anti-ice fix, paving way for deliveries
Novavax (NVAX) Misses Q3 EPS by 3c
November 9, 2015 9:29 AM ESTNovavax (NASDAQ: NVAX) reported Q3 EPS of ($0.12), $0.03 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $6.53 million versus the consensus estimate of $10.59 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
... MoreNovavax (NVAX) Announces Initiation of RSV F Vaccine Phase 3 in Older Adults
November 9, 2015 6:56 AM ESTNovavax (NASDAQ: NVAX) announced the initiation of a Phase 3 clinical trial, known as Resolve, of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults (60 years of age and older).
The Resolve trial is a randomized, observer-blinded, placebo-controlled trial designed to enroll up to 11,850 older adults at 60 sites in the United States.... More
